Document is current
Any future updates will be listed below
-
Authors
Zilbauer, Matthias https://orcid.org/0000-0002-7272-0547
James, Kylie R. https://orcid.org/0000-0002-7107-0650
Kaur, Mandeep https://orcid.org/0000-0002-9757-4048
Pott, Sebastian https://orcid.org/0000-0002-4118-6150
Li, Zhixin https://orcid.org/0000-0001-9962-3942
Burger, Albert
Thiagarajah, Jay R. https://orcid.org/0000-0002-1437-325X
Burclaff, Joseph https://orcid.org/0000-0002-0325-5039
Jahnsen, Frode L.
Perrone, Francesca
Ross, Alexander D.
Matteoli, Gianluca https://orcid.org/0000-0002-2902-4976
Stakenborg, Nathalie https://orcid.org/0000-0002-6229-0045
Sujino, Tomohisa https://orcid.org/0000-0003-0699-6577
Moor, Andreas https://orcid.org/0000-0001-8715-8449
Bartolome-Casado, Raquel https://orcid.org/0000-0002-8966-9047
Bækkevold, Espen S.
Zhou, Ran https://orcid.org/0000-0002-0562-4483
Xie, Bingqing
Lau, Ken S. https://orcid.org/0000-0001-8438-0319
Din, Shahida https://orcid.org/0000-0003-2855-3400
Magness, Scott T.
Yao, Qiuming
Beyaz, Semir
Arends, Mark https://orcid.org/0000-0002-6826-8770
Denadai-Souza, Alexandre https://orcid.org/0000-0003-0385-1321
Coburn, Lori A. https://orcid.org/0000-0003-3249-9806
Gaublomme, Jellert T.
Baldock, Richard https://orcid.org/0000-0003-0332-6877
Papatheodorou, Irene https://orcid.org/0000-0001-7270-5470
Ordovas-Montanes, Jose https://orcid.org/0000-0001-5444-5601
Boeckxstaens, Guy https://orcid.org/0000-0001-8267-5797
Hupalowska, Anna
Teichmann, Sarah A. https://orcid.org/0000-0002-6294-6366
Regev, Aviv
Xavier, Ramnik J. https://orcid.org/0000-0002-5630-5167
Simmons, Alison
Snyder, Michael P. https://orcid.org/0000-0003-0784-7987
Wilson, Keith T. https://orcid.org/0000-0003-4421-1830
,
,
- License Information
-
More Information
Article History
Accepted: 14 April 2023
First Online: 31 May 2023
Competing interests
: In the past 3 years, S.A.T. has consulted or been a member of scientific advisory boards at Roche, Genentech, Biogen, GlaxoSmithKline, Qiagen and ForeSite Labs and is an equity holder of Transition Bio. G.M. has received grant funding from Boehringer Ingelheim. A. Regev is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and was a SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov until 31 July 2020. Since 1 August 2020, A. Regev has been an employee of Genentech and has equity in Roche. A. Regev is an inventor on patents and patent applications filed at the Broad Institute related to single-cell genomics. The remaining authors declare no competing interests.
